ABIO - Company Financial Ratios

ARCA biopharma Inc.

ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

United States http://arcabio.com

Healthcare Biotechnology NASDAQ | NASDAQ Capital Market

1.993 10.84

period
2021	4.51	27.26	- 1.06	0.00	0.00	1.15	0.13	- 64.26	- 75.42
2019	5.27	7.00	- 4.83	- 1.27	0.00	0.92	1.12	- 64.22	- 72.04
2018	7.92	110.00	- 8.27	- 13.83	0.24	18.18	0.13	- 116.23	- 131.52
2017	32.40	338.00	- 17.48	- 18.28	0.24	32.89	0.20	- 149.53	- 179.95
2016	45.90	416.00	- 14.99	- 25.31	0.29	18.75	0.11	- 66.77	- 74.09
2015	68.22	429.00	- 10.54	- 37.49	0.30	11.27	0.04	- 28.92	- 30.06